Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 3/20 | 0.35 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.34 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.34 |
| ▸ | AXL | P30530 | 1/20 | 0.33 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.33 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.32 |
| ▸ | HTT | P42858 | 3/20 | 0.32 |
| ▸ | HSP90AA1 | P07900 | 3/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.32 |
| ▸ | APAF1 | O14727 | 1/20 | 0.32 |
| ▸ | TDP2 | O95551 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | CASP3 | P42574 | 1/20 | 0.32 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.32 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.32 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18397039 | 0.88 | GRM4 (0.35) | GRM4ENPP3ENPP1AXLPDK2 | |
| SCHEMBL31068961 | 0.88 | GRM4 (0.35) | GRM4ENPP3ENPP1AXLPDK2 | |
| SCHEMBL29601934 | 0.83 | ENPP3 (0.43) | ENPP3ENPP1AXLPDK2TRPM8 | |
| SCHEMBL12203098 | 0.83 | AXL (0.35) | GRM4AXLKMT2AHTTHSP90AA1 | |
| SCHEMBL1336101 | 0.83 | ENPP3 (0.43) | ENPP3ENPP1AXLPDK2TRPM8 | |
| SCHEMBL14333347 | 0.83 | AXL (0.35) | AXLKMT2AHTTHSP90AA1MEN1 | |
| Bromide SCHEMBL28204049 | 0.81 | ENPP3 (0.42) | ENPP3ENPP1AXLPDK2TRPM8 | |
| SCHEMBL16836001 | 0.79 | SMN1; SMN2 (0.35) | GRM4AXLPDK2KMT2AHTT | |
| SCHEMBL1332467 | 0.79 | AXL (0.33) | AXLKMT2AHTTHSP90AA1MEN1 | |
| SCHEMBL20640057 | 0.77 | TRPM8 (0.37) | GRM4PDK2TRPM8HTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240343741-A1 | LEUCINE-RICH REPEAT KINASE 2 (LRRK2) INHIBITORS | H. LUNDBECK A/S (DK) | 2024-10-17 | — | — | US | disclosed |
| US-11958865-B1 | Leucine-rich repeat kinase 2 (LRRK2) inhibitors | H. LUNDBECK A/S (DK) | 2024-04-16 | — | — | US | disclosed |
| WO-2024056775-A1 | MACROCYCLIC LEUCINE-RICH REPEAT KINASE 2 (LRRK2) INHIBITORS | H. LUNDBECK A/S (DK) | 2024-03-21 | — | — | WO | disclosed |
| WO-2019023468-A1 | TYK2 INHIBITORS AND USES THEREOF | NIMBUS LAKSHMI, INC. (US) | 2019-01-31 | — | — | WO | disclosed |
| US-9688678-B2 | Oxindole compounds carrying a nitrogen-bound spiro substituent and use thereof for treating vasopressin-related diseases | AbbVie Deutschland GmbH & Co. KG (DE) | 2017-06-27 | — | — | US | disclosed |
| EP-3143024-A1 | OXINDOLE COMPOUNDS CARRYING A NITROGEN-BOUND SPIRO SUBSTITUENT AND USE THEREOF FOR TREATING VASOPRESSIN-RELATED DISEASES | AbbVie Deutschland GmbH & Co. KG (DE) | 2017-03-22 | — | — | EP | disclosed |
| US-20150329551-A1 | OXINDOLE COMPOUNDS CARRYING A NITROGEN-BOUND SPIRO SUBSTITUENT AND USE THEREOF FOR TREATING VASOPRESSIN-RELATED DISEASES | AbbVie Deutschland GmbH & Co. KG (DE) | 2015-11-19 | — | — | US | disclosed |
| WO-2015173393-A1 | OXINDOLE COMPOUNDS CARRYING A NITROGEN-BOUND SPIRO SUBSTITUENT AND USE THEREOF FOR TREATING VASOPRESSIN-RELATED DISEASES | AbbVie Deutschland GmbH & Co. KG (DE) | 2015-11-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150329551-A1 | OXINDOLE COMPOUNDS CARRYING A NITROGEN-BOUND SPIRO SUBSTITUENT AND USE THEREOF FOR TREATING VASOPRESSIN-RELATED DISEASES | AVPR2, AVPR1B, AVPR1A | GRM4 2218/4885ENPP3 3577/4885ENPP1 4363/4885 |
| US-20240343741-A1 | LEUCINE-RICH REPEAT KINASE 2 (LRRK2) INHIBITORS | LRRK2, PARK7, PINK1 | GRM4 1626/4885ENPP3 3152/4885ENPP1 3157/4885 |
| US-11958865-B1 | Leucine-rich repeat kinase 2 (LRRK2) inhibitors | LRRK2, PARK7, PINK1 | GRM4 1626/4885ENPP3 3152/4885ENPP1 3157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.